Overview

Lighthouse Biosciences, LLC, is the result of several years of academic research predicated upon the development of in vitro molecular diagnostics for the rapid and accurate detection and screening of pathogenic organisms. The company was founded in the fall of 2005 by three University of Rochester researchers: Christopher M. Strohsahl, Benjamin L. Miller, and Todd D. Krauss. The founders of Lighthouse Biosciences are committed to developing state-of-the-art medical diagnostic instruments that can deliver highly accurate results in minutes to hours as opposed to days. Lighthouse Biosciences will transform medical diagnostics by enabling physicians to diagnose and treat infectious diseases as rapidly and accurately as possible, thereby improving the quality of patient care.

Lighthouse Biosciences' signature technology is the NanoLantern. The Lighthouse NanoLantern is a DNA-based system that targets a particular pathogen, and lights up when the pathogen is detected. Lighthouse Biosciences has developed the NanoLantern technology to be used for rapid, sensitive, and specific detection of pathogenic organisms by specifically leveraging two unique, proprietary aspects of DNA detection that were developed by the company's founders. Lighthouse Biosciences will develop the NanoLantern technology to produce a market beating in vitro diagnostic instrument that can be used in clinical laboratories and hospitals for detection and differentiation of infectious agents.